Prothena CORP Public LTD CO 8-K filings

Prothena Corporation shareholders re-elected directors, ratified the appointment of KPMG LLP, and approved executive compensation at the 2026 Annual General Meeting.

Prothena Corporation plc announced a share repurchase plan of up to $100 million, expiring December 31, 2026, leveraging its strong cash position.

Prothena reported its fourth quarter and full year 2025 financial results, highlighting significant advancements in its partnered clinical programs and providing 2026 financial guidance.

Prothena Corporation plc announced the resignation of Board Director Paula Cobb, effective December 31, 2025.

Prothena Corporation plc shareholders approved a capital reduction to create distributable reserves, enhancing financial flexibility.

Prothena reports Q3 2025 financial results, highlighting significant advancements in its late-stage clinical pipeline and plans for a potential share redemption program.

Prothena announced Phase 1 results for its Alzheimer's drug PRX012, demonstrating amyloid plaque reduction but also higher rates of ARIA-E, leading to a search for partnerships.

Prothena Corporation plc announced that its partner Novo Nordisk will advance coramitug into Phase 3 development for ATTR amyloidosis with cardiomyopathy.

Prothena Corporation plc reported a significant net loss in Q2 2025, driven by restructuring and tax expenses, while advancing its Parkinson's and Alzheimer's disease programs and planning a potential share redemption.

Prothena Corporation plc has entered into new employment agreements with its Chief Strategy & Financial Officer, Chief Operating Officer, and Chief Scientific Officer, formalizing their compensation and severance benefits.

Prothena Corporation plc announced a significant 63% workforce reduction and executive departures, expecting $16 million to $20 million in related charges, following its decision to discontinue the birtamimab development program.

Prothena Corporation plc announced that its partner Roche will advance prasinezumab, an investigational anti-alpha-synuclein antibody, into Phase III development for early-stage Parkinson's disease.

Prothena Corporation plc announced the discontinuation of its birtamimab program following the failure of its Phase 3 AFFIRM-AL clinical trial to meet its primary and secondary endpoints in patients with AL amyloidosis.

Prothena Corporation's shareholders approved an amendment to the 2018 Long Term Incentive Plan, increasing the number of ordinary shares authorized for issuance by 2,000,000.

Prothena Corporation plc announced its first quarter 2025 financial results, highlighting progress in its clinical programs and upcoming milestones.

Prothena announced its Q4 and full year 2024 financial results, highlighting R&D progress and providing financial guidance for 2025, including expected clinical milestones and cash usage.

Oleg Nodelman has resigned from Prothena Corporation's Board of Directors, effective December 31, 2024, to pursue other opportunities.

Prothena announced its third quarter 2024 financial results, highlighting a net loss of $59.0 million and providing updates on its clinical programs, including multiple expected data readouts in 2025.

Prothena Corporation plc announced the resignation of its Chief Medical Officer, Hideki Garren, and the appointment of Chad Swanson as Chief Development Officer, effective September 27, 2024.

Prothena's second quarter of 2024 saw a significant increase in revenue and a shift to net income, driven by a major licensing agreement with Bristol Myers Squibb and continued advancement of its clinical programs.

Prothena grants Bristol Myers Squibb an exclusive global license for its PRX019 program, securing an $80 million upfront payment and potential for over $600 million in milestones and royalties.

Prothena Corporation's shareholders approved an amendment to the 2018 Long Term Incentive Plan, increasing the number of shares available for issuance by 2,000,000, and re-elected four directors at the annual general meeting.

Prothena announced its first quarter 2024 financial results, highlighting advancements in its Alzheimer's and amyloidosis programs, and a net loss of $72.2 million.

Prothena Corporation has appointed Daniel G. Welch as a director and Chair Designate, with plans to make him Chair of the Board after the next shareholder meeting.

Prothena announced its fourth quarter and full year 2023 financial results, along with 2024 financial guidance, highlighting progress in its clinical pipeline and a strong cash position.